- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe active rheumatoid arthritis
- Meeting Date: December 2023
- Public Summary Document (PSD) December 2023 PBAC Meeting - (PDF 667KB)
- Public Summary Document (PSD) December 2023 PBAC Meeting - (Word 593KB)
Upadacitinib – December 2023
Upadacitinib: Tablet 15 mg; Rinvoq®
Last updated
30 May 2025